Edward V Prochownik

7872027, Jan 18, 2011

Feb 16, 2007

11/707421

Steven J. Metallo - Silver Springs MD, US
Edward V. Prochownik - Pittsburgh PA, US

University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
Georgetown University - Washington DC

A61K 31/427
A61K 31/445
C07D 277/08
C07D 417/02

514326, 546184, 546192, 546209, 548146, 548182, 548183, 514315, 514365, 514369

Compounds and compositions for interfering with the association of Myc and Max are described herein. These compounds and compositions are useful in methods inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell are provided, comprising contacting the cell with an amount of a compound that interferes with Myc and Max association effective to inhibit growth or proliferation of the cell.

8637556, Jan 28, 2014

Jan 15, 2010

13/144674

Steven J. Metallo - Silver Spring MD, US
Edward V. Prochownik - Pittsburgh PA, US
Ariele Viacava Follis - Memphis TN, US

University of Pittsburgh—Of the Commonwealth System of Higher Education - Pittsburgh PA
Georgetown University - Washington DC

A61K 31/427
A61K 31/4245
C07D 277/04
C07D 413/02

514364, 514369, 548126, 548183, 435375

Provided herein are compounds and compositions for interfering with the association of Myc and Max. These compounds and compositions are useful in methods for inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell comprise contacting the cell with an amount of a compound that interferes with Myc and Max association effective to inhibit growth or proliferation of the cell.

20040034060, Feb 19, 2004

Jun 12, 2003

10/459769

Edward Prochownik - Pittsburgh PA, US
Christine Giap - Pittsburgh PA, US
John Lazo - Pittsburgh PA, US
Xiaoying Yin - Chapel Hill NC, US

A61K031/445
A61K031/427
A61K031/4245
A61K031/137

514/317000, 514/364000, 514/369000, 514/424000, 514/649000

The c-Myc oncoprotein, a helix-loop-helix-leucine zipper (HLH-ZIP) transcription factor, is frequently deregulated in human cancers. All known functions of c-Myc, including those pertaining to transformation, require that it heterodimerize with another HLH-ZIP protein, Max. Using a high throughput yeast-based assay, we identified seven low molecular weight substances that inhibit c-Myc-Max association. Each compound also prevented this interaction in vitro and inhibited the growth of c-Myc-expressing fibroblasts, although not of fibroblasts lacking c-Myc. Finally, short-term exposure of c-Myc over expressing fibroblasts to several of the compounds markedly reduced their in vivo tumorigenicity. These studies suggest that yeast-based assays can be used to identify inhibitors of protein-protein interactions and that these frequently function in mammalian cells. The signature specificities of each of the c-Myc-Max compounds identified here further suggest synergistic in vivo function.

20100298352, Nov 25, 2010

May 6, 2010

12/775023

Edward V. Prochownik - Pittsburgh PA, US
John S. Lazo - Pittsburgh PA, US

A61K 31/52
A61K 31/353
A61P 35/00

5142634, 514456

A method of inhibiting a carcinoma in a subject, comprising administering to the subject at least one therapeutic agent that selectively targets carcinoma stem cells. Illustrative carcinoma stem cell-selective therapeutic agents include CGP74514A, rottlerin, and A-77636.

20110244472, Oct 6, 2011

Nov 10, 2010

12/927225

Edward A. Prochownik - Pittsburgh PA, US

C12Q 1/68
C12N 5/095
C12N 5/10
C12N 15/85
C12Q 1/18
G01N 33/574

435 613, 435325, 4353201, 435 32, 435 723

The present invention relates to the preparation and use of immortalized cancer stem cells. The immortalized cancer stem cells of the invention may be used in assays to identify anti-cancer compounds as well as molecules critical to carcinogenesis. Further, cancer stem cells may be harvested from a patient and used, according to the invention, to select agents more likely to be effective in treating the cancer of that particular patient.